<DOC>
	<DOCNO>NCT00821054</DOCNO>
	<brief_summary>This study randomize 3-treatment , cross-over study evaluate bioavailability lapatinib administer high low-fat meal .</brief_summary>
	<brief_title>A Study Examine Effects Low High-fat Meals Orally Administered Lapatinib Metastatic ErbB2 Positive Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Metastatic , histologically confirm breast cancer overexpresses ErbB2 ( 3+ IHC ; FISH CISH positive ) . Is least 18 year age great 65 year age . Is male female . A female eligible enter participate study : 1 . Nonchildbearing potential ( i.e . physiologically incapable become pregnant ) , include female : hysterectomy ; bilateral oophorectomy ( ovariectomy ) ; bilateral tubal ligation , postmenopausal ( demonstration total cessation menses ≥ 1 year ) questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory . 2 . Childbearing potential , negative serum pregnancy test Screening agree one following : doublebarrier contraception ( condom spermicidal jelly , foam , suppository , film ; diaphragm spermicide ; male condom diaphragm ) ; complete abstinence sexual intercourse two week prior administration study drug , throughout active study treatment period ; vasectomized partner sterile prior female subject 's entry sole sexual partner female . Is able swallow retain oral medication . ECOG performance status 0 2 . Adequate bone marrow function . Hemoglobin ≥ 9 gm/dL . Absolute granulocyte count ≥1,500/mm3 ( 1.5 x 109/L ) . Platelets ≥ 75,000/mm3 ( 75 x 109/L ) . Calculated creatinine clearance ( CrCl ) ≥ 50 ml/min base Cockcroft Gault Total bilirubin ≤ 1.5 X upper limit normal institutional value INR ≤ 1.5 . Alanine transaminase ( ALT ) ≤ three time upper limit institutional value ≤ five time ULN document liver metastasis . Has leave ventricular ejection fraction ( LVEF ) within normal institutional range base ECHO MUGA . Life expectancy ≥12 week Capable give write informed consent , include compliance requirement restriction list consent form . Is pregnant lactating . Has malabsorption syndrome , disease affect gastrointestinal function , resection stomach small bowel . Has current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) . Has evidence symptomatic uncontrolled brain metastasis leptomeningeal disease . Subjects brain metastasis treat surgery and/or radiotherapy eligible neurologically stable require steroid anticonvulsant . Is consider medically unfit study investigator result medical interview , physical exam , screen investigation . Has know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate investigational product gefitinib [ Iressa ] erlotinib [ Tarceva ] . Has receive treatment investigational drug previous four week . Has receive chemotherapy , immunotherapy , biologic therapy hormonal therapy treatment cancer within past 14 day , exception mitomycin C restrict past six week . Is receive prohibit medication within timeframe indicate prohibited medication list study . Has physiological , familial , sociological , geographical condition permit compliance protocol . Has inadequate venous access protocolrelated blood draw . Clinically significant electrocardiogram ( ECG ) abnormality . History sensitivity heparin heparininduced thrombocytopenia . Has consume red wine , seville orange , grapefruit grapefruit juice and/or kumquat , pummelo , exotic citrus fruit ( i.e . star fruit , bitter melon ) , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Phase I Food Effect</keyword>
</DOC>